A new publication involving elamipretide, also known as SS-31, appeared in the journal Biology on June 28, 2026. The paper is titled "Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence." It is indexed under PubMed ID 42450582. The publication is listed as a new addition to the scientific literature on elamipretide. No specific findings, results, or conclusions from the study are detailed here. Elamipretide is currently classified as an approved compound. This brief reports only the existence and bibliographic details of the publication, including its title, journal, and publication date. Readers interested in the underlying research should consult the original article directly through the linked source for full methodology and results. For additional background on elamipretide, including its regulatory status and general profile, readers can refer to the compound overview.
Elamipretide (SS-31) Study Published on H9C2 Cell Senescence
See the full elamipretide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42450582/